Pharmacokinetics of a new sublingual formulation of temazepam.
The pharmacokinetics of a new 10 mg sublingual tablet formulation of temazepam and those of a currently marketed 10 mg oral capsule formulation were evaluated in a group of ten healthy volunteers. No significant differences were observed between the two formulations with respect to any of the pharmacokinetic parameters assessed. Lethargy and somnolence were reported on both capsule and tablet by several subjects at a time which corresponded with the maximum concentration of drug in plasma. The data indicate that the sublingual tablet and orally administered capsule have a similar pharmacokinetic and pharmacodynamic profile.
Russell
W J
WJ
Department of Anaesthesia and Intensive Care, Royal Adelaide Hospital, South Australia.
Badcock
N R
NR
Frewin
D B
DB
Sansom
L N
LN
D000284:Administration, Oral; D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011897:Random Allocation; D013693:Temazepam / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
D014151:Anti-Anxiety Agents; D013693:Temazepam